AstraZeneca, Daiichi's Trodelvy rival fails to improve overall survival in breast cancer trial
AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival (OS) in a phase 3 trial. The latest miss happened in breast cancer, a setting in which Gilead’s rival Trodelvy significantly improved OS in a prior late-phase study.
The partners said their antibody-drug conjugate datopotomab deruxtecan didn’t extend survival in a breast cancer study, ...
Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...
A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...
Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...
Discover Daiichi Sankyo's groundbreaking patent for monoclonal antibodies targeting LAG-3, offering new hope for treating autoimmune diseases with enhanced efficacy.
Daiichi Sankyo has launched a new direct-to-consumer (DTC) campaign for Enhertu — the first DTC effort for its oncology unit ...
As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...
Japan and China said Friday they have reached a deal toward resolving their disputes over the discharge of treated ...
ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.
Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal in a late-stage study in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback